FlexPen outperforms SoloSTAR in studies

NEW YORK Sanofi-aventis’ SoloSTAR insulin pen has some serious competition.

Two independent studies in Germany and Japan have found that Novo Nordisk’s FlexPen was more accurate in delivering insulin to diabetes patients than SoloSTAR. The German study found that FlexPen delivered insulin more accurately at 10-unit and 30-unit doses. The Japanese study also tested at five-unit doses, producing similar results for all three.

Both studies used pens filled with respective insulin brands, namely Levemir for the FlexPen and Lantus for the SoloSTAR.